Resource Category: NASH

Pharmacokinetic and Pharmacodynamic Response in Individual NASH Patients Receiving Two Dose Levels of DUR-928 

Safety and pharmacokinetics of DUR-928 in patients with non-alcoholic steatohepatitis– A Phase 1b study 

DUR-928, an endogenous regulatory molecule, exhibits anti-inflammatory and antifibrotic activity in a mouse model of NASH